• P. N. Patsalos


Primidone (Fig. 1) corresponds chemically to 5-ethyldihydro-5-phenyl-4,6(1-H,5H)pyrimidine-dione with an empirical formula of C12H14N2O2 and a molecular weight of 218.25.


Valproic Acid Therapeutic Drug Monitoring Pharmacokinetic Interaction Dose Ratio Eslicarbazepine Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Syversen GB, Morgan JP, Weintraub M, Myers GJ. Acetazolamide-induced interference with primidone absorption. Case reports and metabolic studies. Arch Neurol. 1977;34:80–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Battino D, Avanzini G, Bossi L, Croci D, Cusi C, Gomeni C, Moise A. Plasma levels of primidone and its metabolite phenobarbital: effect of age and associated therapy. Ther Drug Monit. 1983;5:73–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Theis JGW, Koren G, Daneman R, Sherwin AL, Menzano E, Cortez M, Hwang P. Interactions of clobazam with conventional antiepileptics in children. J Child Neurol. 1997;12:208–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Nanda RN, Johnson RH, Keogh HJ, Lambie DG, Melville ID. Treatment of epilepsy with clonazepam and its effect on other anticonvulsants. J Neurol Neurosurg Psychiatry. 1977;40:538–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (lamictal) for refractory partial seizures. Epilepsia. 1989;30:356–63.PubMedCrossRefGoogle Scholar
  6. 6.
    Perucca E, Baltes E, Ledent E. Levetiracetam: absence of pharmacokinetic interactions with other antiepileptic drugs (AEDs). Epilepsia. 2000;41(Suppl):150.Google Scholar
  7. 7.
    Browne TR, Feldman RG, Buchanan RA, Allen NC, Fawcett-Vickers L, Szabo GK, Mattson GF, Norman SE, Greenblatt DJ. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983;33:414–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Fincham RW, Schottelius DD, Sahs AL. The influence of diphenylhydantoin on primidone metabolism. Arch Neurol. 1974;30:259–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Levy RH, Loiseau P, Guyot M, Blehaut H, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36:661–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Summary of product characteristics – Sulthiame/Ospolot. 2009.Google Scholar
  11. 11.
    Doose DR, Walker SA, Pledger G, Lim P, Reife RA. Evaluation of phenobarbital and primidone/phenobarbital (primidone active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multicenter, double-blind, placebo controlled trials in outpatients with partial seizures. Epilepsia. 1995;36 (Suppl 3):158.Google Scholar
  12. 12.
    Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, Penry JK. Mechanism of valproate–phenobarbital interaction in epileptic patients. Clin Pharmacol Ther. 1981;29:480–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Matilainen R, Pitkanen A, Ruutiainen T, et al. Effect of vigabatrin on epilepsy in mentally retarded patients: a 7-month follow-up study. Neurology. 1988;38:743–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, Egli M, Basuer G, Stenzel E, Blankenhorn V. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15:67–73.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations